Pharma Merger

Directors are selling Dermira, a biopharmaceutical company, too cheaply through an unfair process to nonparty Eli Lilly, for $18.75 a share or $1.1 billion, a shareholder claims in federal court.

SAN FRANCISCO — Directors are selling Dermira, a biopharmaceutical company, too cheaply through an unfair process to nonparty Eli Lilly, for $18.75 a share or $1.1 billion, a shareholder claims in federal court.

Categories / Business, Securities

Subscribe to Closing Arguments

Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.

Pharma Merger

Subscribe to Closing Arguments

Additional Reads